Vanda Pharmaceuticals Inc.
) reported fourth quarter 2013 net loss per share of 23 cents,
flat year over year. The reported loss was wider than the Zacks
Consensus Estimate of a loss of 18 cents.
Fourth quarter revenues of $8.8 million were above the
year-ago revenues of $7.9 million. Revenues surpassed the Zacks
Consensus Estimate of $8 million. Revenues included Fanapt
) worth $2 million in the reported quarter, above year-ago
royalties of $1.2 million.
According to IMS, Fanapt prescriptions for the fourth quarter
were roughly 43,400, up 14% year over year but down 1%
Research and development expenses were $6.2 million, down
41.4% from the year-ago quarter. The decrease was attributable to
the completion of efficacy studies for Hetlioz in the treatment
of Non-24-Hour sleep-wake disorder (Non-24) and major depressive
disorder. We note that the U.S. Food and Drug Administration
(FDA) approved Hetlioz 20mg in Jan 2014 for the treatment of
Non-24. Hetlioz, the first and only FDA approved medication for
Non-24, will be launched in the second quarter of 2014. Vanda
expects to file a Marketing Authorisation Application (MAA) with
the European Medicines Agency (EMA) for Hetlioz (Non-24) in
General and administrative expenses increased to $9.9 million
from $3.2 million in the year-ago quarter mainly due to rising
commercial activities for the U.S. launch of Hetlioz.
An interesting candidate in Vanda's pipeline is VLY-686. Vanda
has initiated a proof of concept study for VLY-686 in the
treatment resistant pruritus in atopic dermatitis.
Vanda reported a full year 2013 loss of 67 cents per share,
wider than the Zacks Consensus Estimate of a loss of 63 cents but
narrower than the 2012 loss of 98 cents per share.
Full year revenues were $33.9 million, almost at par with the
Zacks Consensus Estimate of $34 million. Revenues in 2012 were
$32.7 million. Revenues included Fanapt royalties from Novartis
worth $7.1 million in 2013, above year-ago royalties of $5.9
Vanda carries a Zacks Rank #3 (Hold). The year 2014 will be
eventful for Vanda as it launches Hetlioz in the U.S. Investors
looking for better-ranked stocks in the biopharma sector may
consider companies like
Biogen Idec Inc.
). Both companies carry a Zacks Rank #1 (Strong Buy).
BIOGEN IDEC INC (BIIB): Free Stock Analysis
ENDOCYTE INC (ECYT): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
VANDA PHARMACT (VNDA): Free Stock Analysis
To read this article on Zacks.com click here.